Conditions

High-Flow AV Fistula

AV fistulas are widely used for hemodialysis access, but some fistulas develop access flows well above what dialysis requires — and that excessive flow can increase cardiac workload in susceptible patients.

AV fistulas are widely considered the preferred form of hemodialysis access where anatomically feasible, in part because of their durability and patency. As a fistula matures, the vein remodels under arterial pressure, and access flow rises. In most patients this is exactly what's wanted. In a subset of patients, however, the fistula matures to or develops a high access flow that delivers far more blood per minute than dialysis requires. That excess flow is not a problem for the dialysis machine itself; it is a continuous load on the heart.

What is a high-flow AV fistula?

A high-flow AV fistula is an AV fistula whose dialysis access flow is significantly above what is needed for adequate hemodialysis. Historically, the field has described high-flow using fixed thresholds such as 1.5 to 2.0 L/min, but recent clinical discussion — including at the Vascular Access Society of the Americas (VASA) — has emphasized that the more important standard is the physiologic effect on the patient, not the access-flow number alone.

A given fistula flow may be well tolerated in one patient and impose meaningful cardiac stress in another. Cardiac reserve, age, valve disease, pre-existing pulmonary hypertension, and other comorbidities all shape how much continuous high-flow AV access an individual heart can absorb without consequence.

Why fistula flow matters

The volume of blood moving through an AV fistula — the fistula flow — is the most direct driver of the cardiac load the access creates. The dialysis machine pulls a few hundred milliliters per minute through the dialyzer during a treatment session; everything beyond that, present 24 hours a day, is continuous extra flow the heart has to support.

Fistula flow is therefore both essential and a variable to be watched. Surveillance of access flow alongside cardiac function is more informative than a single threshold, because what looks like a tolerable number on a flow study may be poorly tolerated by a heart with limited reserve.

High-flow fistulas and cardiac burden

The continuous extra flow created by a high-flow fistula increases cardiac workload, because the heart must pump a larger volume per minute to perfuse the rest of the body. Sustained increases in cardiac output demand can produce changes in cardiac structure and function over time. Cardiac remodeling is most often discussed in this context, along with pulmonary hypertension, which can develop alongside the elevated venous return that high-flow AV access creates.

In some patients, the cumulative load contributes to high-output heart failure — a clinical state in which the heart pumps more blood than usual yet still cannot meet the body's needs. The relationship is not deterministic: many patients tolerate AV fistulas, including some with significant access flow, without developing these complications. The same physiology applies to grafts; for that view, see high-flow AV graft. For deeper background, see cardiac burden of AV fistulas and AV grafts and high-output heart failure and dialysis access.

Symptoms and clinical concerns

Symptoms sometimes associated with a high-flow AV fistula and the cardiac burden it can create include:

These symptoms can have many causes and are not diagnostic of high-output heart failure by themselves. Any new or worsening symptoms in a hemodialysis patient with an AV fistula warrant evaluation by a physician familiar with the patient's history. This page is informational and is not medical advice.

Why fixed thresholds may not tell the whole story

A single number — for example, 1.5 L/min — is convenient as a definition of high-flow, but it can miss patient-specific risk. Two issues with fixed thresholds are increasingly discussed in the field:

A patient-centered framing — judging high-flow by its physiologic effect on the heart, not by the access-flow number alone — better captures the cardiac burden any given fistula creates in any given patient.

Access flow reduction

Access flow reduction is a clinical strategy that lowers the volume of blood moving through a high-flow AV fistula while preserving the access for hemodialysis. Approaches may include banding, surgical revision, or other flow-reduction procedures, depending on the patient and the fistula anatomy. The intent is to reduce continuous cardiac burden without sacrificing the access. Access flow reduction has historically been pursued reactively, after symptoms or complications appear; the underlying clinical question is the same regardless of timing.

Endovascular flow-control and flow-control stents

Endovascular flow-control refers to reducing excessive dialysis access flow through a device placed inside the vessel, delivered via the vascular system rather than through open surgical revision. A flow-control stent is one example: rather than being placed to treat stenosis or maintain patency, its geometry is designed to limit access flow from inside the existing fistula or access circuit, while preserving the access for hemodialysis.

An endovascular flow-control option may be attractive for high-flow AV fistulas because many of the patients most likely to benefit already have established access circuits — meaning flow-control can potentially be introduced without recreating the fistula surgically. Elastic flow-control stents are an investigational example of this approach; they are in development and have not received FDA clearance or approval.

VascX and flow-control dialysis access

For an established high-flow AV fistula, the practical question is how to introduce flow-control without sacrificing a working access. VascX's elastic flow-control stents are designed for exactly that situation — an endovascular flow-control option intended to be delivered into an existing fistula or access circuit and limit access flow from inside the vessel, while leaving the access functional for hemodialysis. The stent sits within VascX's broader flow-control dialysis access platform, which also includes elastic flow-control grafts for new access creation.

VascX products are investigational. The company does not claim that its devices are proven to treat or prevent cardiac remodeling, pulmonary hypertension, high-output heart failure, hospitalization, mortality, or access failure. The platform is designed to address the underlying physiology — dialysis access flow — that the field increasingly views as relevant to cardiac outcomes in hemodialysis patients.

Frequently asked questions

What is a high-flow AV fistula?

A high-flow AV fistula is an arteriovenous fistula whose access flow is significantly above what is needed for adequate hemodialysis. Historically, the field has defined high-flow using fixed thresholds such as 1.5 to 2.0 L/min, but recent clinical discussion suggests that the relevant standard is the physiologic effect on the patient — particularly on the heart — not the access-flow number alone. A given fistula flow may be tolerated in one patient and impose a meaningful cardiac burden in another.

Why can an AV fistula increase cardiac workload?

An AV fistula creates a low-resistance connection between an artery and a vein, allowing blood to bypass the high-resistance capillary bed. To maintain perfusion to the rest of the body, the heart must pump a larger total volume per minute. This added cardiac output demand is continuous — present 24 hours a day for as long as the fistula is in place — and can increase cardiac workload over time, particularly when fistula flow is high.

Can a high-flow fistula contribute to high-output heart failure?

In some patients, yes. A high-flow AV fistula can contribute to high-output heart failure by adding a continuous, non-physiologic flow load on top of any underlying cardiovascular disease. Cardiac remodeling and pulmonary hypertension are commonly discussed in this context as well, and can precede or accompany high-output heart failure in susceptible patients. The relationship is not deterministic — many patients tolerate AV fistulas without progressing to heart failure — but the field increasingly recognizes the fistula circuit itself as a relevant cardiac variable.

What symptoms may be associated with a high-flow AV fistula?

Symptoms that may be associated with a high-flow AV fistula and the cardiac burden it can create include shortness of breath, fatigue, exercise intolerance, and signs of heart failure such as fluid retention or reduced functional capacity. Some patients may also show signs of pulmonary hypertension. These symptoms have many possible causes and are not specific to high-flow fistulas. Patients experiencing these symptoms should consult their physician for evaluation.

What is access flow reduction for a high-flow fistula?

Access flow reduction in a high-flow AV fistula is a clinical strategy that lowers the volume of blood moving through the fistula while preserving its function for hemodialysis. Approaches may include banding, surgical revision, or other flow-reduction procedures, depending on the patient and the fistula anatomy. The goal is to reduce continuous cardiac burden without sacrificing the access. Treatment decisions should be made by the patient's care team; this page is not medical advice.

What is endovascular flow-control?

Endovascular flow-control refers to reducing excessive dialysis access flow through a device placed inside the vessel, rather than through open surgical revision. A flow-control stent is one example: it is delivered through the vascular system into the existing fistula or access circuit and is intended to limit access flow from inside the vessel while preserving the access for hemodialysis.

What is a flow-control stent?

A flow-control stent is an endovascular stent whose primary design intent is to limit access flow, rather than to treat stenosis or hold a vessel open. Placed into an existing AV fistula or access circuit, a flow-control stent is intended to reduce excessive dialysis access flow while preserving the function of the access for hemodialysis. VascX is developing elastic flow-control stents as part of an investigational platform; they are not cleared or approved by the U.S. Food and Drug Administration.

Are VascX products FDA-cleared?

VascX products are currently in development and are not yet cleared or approved by the U.S. Food and Drug Administration.

Related VascX resources

Medical disclaimer: This page is for informational purposes only and is not medical advice. Patients should consult their physician about dialysis access symptoms, heart failure symptoms, or access flow concerns.
Investigational status: VascX products are currently in development and are not yet cleared or approved by the U.S. Food and Drug Administration.